Loading...
•
Jun 30, 2023
Humacyte Q2 2023 Earnings Report
Announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.
Key Takeaways
Humacyte reported no revenue for Q2 2023. Enrollment was completed in the Phase 2/3 V005 trial of HAV™ in Vascular Trauma Repair. Top-line results are expected in Q3 2023, followed by a planned BLA filing in Q4 2023. Cash and cash equivalents were $114.6 million as of June 30, 2023.
Completed enrollment in Phase 2/3 clinical trial of HAV in vascular trauma repair.
Presented success in treating wartime injured in Ukraine using HAV under humanitarian aid program.
Published study supporting infection resistance of HAV in the Journal of Vascular Surgery – Vascular Science.
Advanced Type 1 Diabetes Research through collaboration with JDRF International to develop Biovascular Pancreas (BVP).
Forward Guidance
Humacyte believes that its cash and cash equivalents and expected funding from the Oberland funding agreement are adequate to fund operations past the anticipated timelines for potential FDA approval and commercialization of the HAV in the vascular trauma indication.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...